Why Stack TB-500 and BPC-157?
Most peptide combinations used in biohacking are additive at best — two compounds that do similar things, with modest synergy. The TB-500 and BPC-157 stack is different. These two peptides operate through fundamentally distinct mechanisms at different points in the healing cascade, which means running them together produces effects that neither compound achieves alone.
The core logic: BPC-157 drives localized tissue repair at injury sites through the nitric oxide system, angiogenesis, and growth factor receptor modulation. TB-500 (the synthetic form of Thymosin Beta-4) provides systemic cell migration and proliferation signals that mobilize repair cells throughout the body. BPC-157 tells the injured tissue to rebuild; TB-500 tells the body's repair machinery where to go and how to get there. Together they address the full healing cascade.
- Activates nitric oxide system at injury site
- Promotes angiogenesis (new blood vessels)
- Upregulates growth factor receptors
- Accelerates tendon-to-bone attachment
- Protects and repairs gut mucosal lining
- Sequesters actin to enable cell migration
- Recruits satellite cells for muscle repair
- Reduces systemic inflammation broadly
- Promotes cardiac and connective tissue healing
- Improves flexibility and range of motion
Research on both compounds is cataloged on PubMed. The combination has become the default starting protocol for biohackers dealing with acute injury, chronic joint degeneration, or training-related tissue breakdown — precisely because the mechanism complementarity is so clean.
Context: All research on TB-500 and BPC-157 is preclinical (animal models) as of 2026. This article reflects the research-based rationale and community protocol data. This is not medical advice — consult a qualified healthcare provider before starting any peptide protocol.
TB-500 Dosing Guide
TB-500 is used in two distinct phases: a loading phase with higher, more frequent dosing to saturate tissue and initiate the healing response, followed by a maintenance phase at lower frequency to sustain the effect.
Loading phase (weeks 1–6)
- Dose: 2–2.5 mg per injection
- Frequency: Twice weekly on non-consecutive days (e.g., Monday and Thursday)
- Total weekly dose: 4–5 mg
- Duration: 4–6 weeks
Maintenance phase (weeks 7–10)
- Dose: 2 mg per injection
- Frequency: Once weekly
- Total weekly dose: 2 mg
- Duration: 4 weeks, then off for 4 weeks
Administration is subcutaneous injection — typically into the abdomen. TB-500 can also be injected near the injury site, though systemic distribution via abdominal injection is effective regardless of injection location due to the peptide's systemic mechanism of action.
BPC-157 Dosing in the Stack
BPC-157 runs daily throughout the entire stack cycle, providing consistent localized repair signaling while TB-500 delivers its twice-weekly systemic pulses. The two compounds operate on different schedules and through different mechanisms, so there is no interaction or timing constraint between them.
Standard dosing in the stack
- Dose: 250–500 mcg per injection
- Frequency: Once daily
- Route: Subcutaneous injection (abdomen or near injury site)
- Timing: Morning, or 30 minutes pre-training if targeting training recovery
BPC-157 can be injected at the same abdominal site as TB-500 or at a different site on the same day — there is no pharmaceutical reason to separate them. Many practitioners inject both on TB-500 days at the same time, and inject only BPC-157 on the remaining days.
For users targeting gut healing alongside musculoskeletal repair, oral BPC-157 arginate salt (500 mcg–1 mg/day on an empty stomach) can be added to the injectable protocol. See the complete BPC-157 protocol guide for full injection vs oral breakdown, reconstitution instructions, and storage protocol.
Timing and Cycling the Stack
The full protocol runs both compounds simultaneously on the same overall cycle. The key is understanding that BPC-157 is daily while TB-500 is twice weekly — these are separate schedules within the same cycle window, not alternating protocols.
Full stack schedule
| Compound | Dose | Frequency | Route | Phase |
|---|---|---|---|---|
| TB-500 | 2–2.5 mg | 2× weekly | SubQ injection | Weeks 1–6 (loading) |
| TB-500 | 2 mg | 1× weekly | SubQ injection | Weeks 7–10 (maintenance) |
| BPC-157 | 250–500 mcg | Daily | SubQ injection | Weeks 1–10 (full cycle) |
Cycling structure
- Active cycle: 8–10 weeks total (6 weeks loading + 4 weeks maintenance)
- Off period: 4 weeks off both compounds before repeating
- PCT required: No — neither compound affects the HPTA or requires post-cycle therapy
- Bloodwork timing: Baseline before starting; optional recheck at week 8 for inflammatory markers (hs-CRP, IL-6)
Injection day example: On TB-500 days (Monday/Thursday), inject TB-500 and BPC-157 at the same time — one in each side of the abdomen, or sequentially at the same site. On non-TB-500 days, inject BPC-157 only. Total injections per week: 9 (7× BPC-157 + 2× TB-500).
What Results to Expect
The TB-500 + BPC-157 stack produces a consistent pattern of results that has been reported across thousands of community users and is mechanistically consistent with what the preclinical research predicts. The timeline and magnitude vary by individual, severity of the target issue, and protocol adherence.
Typical timeline
- Days 5–14: Reduced acute inflammation and soreness. Many users notice improved sleep quality in the first two weeks, likely from systemic anti-inflammatory effects.
- Weeks 2–4: Noticeable improvement in joint comfort and range of motion. Tendon stiffness reduction is commonly reported at this stage. Gut symptoms (if BPC-157 oral is included) often improve within the first 2 weeks.
- Weeks 4–8: Structural tissue repair becomes apparent — tendons that were chronically tender begin to normalize, muscle recovery between sessions accelerates measurably, and training volume capacity increases without proportional soreness accumulation.
- Post-cycle: Effects are not purely transient. Tissue that has been structurally repaired stays repaired after the cycle ends. The anti-inflammatory benefit fades faster than the structural changes.
Primary outcomes reported
- Tendon and ligament repair: The most consistently reported benefit — chronic tendinopathy, rotator cuff issues, patellar tendon problems, and Achilles injuries respond particularly well
- Reduced training inflammation: Faster soreness clearance, less cumulative joint stress from high-volume training
- Improved range of motion and flexibility: TB-500's actin-sequestration mechanism directly improves cellular mobility, which translates to measurable flexibility improvements within 3–4 weeks
- Gut health (BPC-157 secondary benefit): Users with concurrent GI issues — leaky gut, gastric discomfort, IBS symptoms — often report significant improvement as a secondary benefit of the BPC-157 component
- Wound and skin healing: Surgical sites, chronic skin wounds, and post-procedural recovery are accelerated
Who Should Consider This Stack?
The TB-500 + BPC-157 stack is not a beginner wellness supplement — it is a precision peptide protocol aimed at specific biological outcomes. It is best suited to:
Athletes recovering from injury
If you have a tendon, ligament, or muscle injury that is not healing at a satisfactory rate — or that has become chronic — this stack is the most mechanistically targeted intervention available outside of surgery or pharmaceutical intervention. The combination of local repair (BPC-157) and systemic cell recruitment (TB-500) addresses the two main reasons soft tissue injuries stall: inadequate blood vessel formation at the repair site, and insufficient recruitment of repair cells from circulation.
Biohackers over 40 with chronic joint issues
Age-related joint degeneration is accelerated by two factors: declining growth factor signaling and accumulating low-grade inflammation. BPC-157 addresses the first; TB-500 addresses the second. For biohackers dealing with chronic knee, shoulder, hip, or elbow issues that have persisted despite conservative management, this stack targets the biological root causes rather than masking symptoms. This is a protocol used by serious biohackers for exactly this purpose — not a casual experiment.
Users with concurrent gut and musculoskeletal issues
If you have GI inflammation alongside musculoskeletal problems — a common combination in high-training-volume athletes and biohackers with high-stress lifestyles — the BPC-157 component of this stack addresses both simultaneously. Oral BPC-157 arginate added to the injectable protocol gives you gut-targeted delivery alongside the systemic injection benefits. The NIH has indexed substantial research on BPC-157's GI mucosal protective mechanisms, distinct from its musculoskeletal effects.
Who should NOT use this stack: Anyone without a specific recovery or repair target. These are research peptides with meaningful cost and administration requirements. If you do not have a clear therapeutic target — an injury, chronic joint issue, or gut condition — a more general wellness protocol is more appropriate. Use the Rate My Stack tool to evaluate whether this combination fits your specific goals.
Track Your Stack Results with BioStackIQ
The TB-500 + BPC-157 stack has two different dosing schedules running simultaneously — daily BPC-157 and twice-weekly TB-500, with a phase transition from loading to maintenance at week 6. Keeping this straight in a calendar app is workable for one cycle; it breaks down when you are adjusting doses based on response, running concurrent oral BPC-157, or trying to compare outcomes across multiple cycles.
BioStackIQ's protocol builder lets you add both compounds as separate entries, set individual frequencies, log each injection, and track outcomes — so your retrospective data is clean and cycle-over-cycle comparisons are meaningful.
- Build your TB-500 + BPC-157 protocol → — free, compound-by-compound setup in under 5 minutes
- Rate My Stack — AI-generated safety and synergy score for your current protocol before you run it